Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 81 | 3.9% |
| Current Price (11/28 4:00PM EST) | $227.41 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 9,971.5 | |||
| Sales Growth Forecast | 5.3% | |||
| Net Profit Margin | 17.4% | |||
| Projected Shares Outstanding | 130.03 | |||
| EPS - Five year Forecast | $17.24 | |||
| Average P/E Ratio | 16.0 | |||
| Projected Average Price | $275.78 | |||
| Price Appreciation (Annualized) | 3.9% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | 3.9% | |||
| Quality | ||||
| Financial Strength | 92 | 22.9 | ||
| EPS Stability | 52 | 12.9 | ||
| Industry Sales Growth Rate | 4.0% | 16.4 | ||
| Industry Net Profit Margin | 19.3% | 11.3 | ||
| Calculated Quality Rating | 63.5 | |||
| Fool CAPS | ||||
Total Players
953
Outperforms
76
Underperforms
All-Stars (208)
195
Outperforms (94%)
13
Underperforms
|
||||
| Fundamental Data Updated: 06/30/2023 | ||||